Observational data based on 13 000 matched pairs from Medicare and MarketScan patients with RA and newly treated with abatacept or a TNF-α inhibitor found benefit of abatacept in MACE restricted to the subgroup with diabetes [HR: 0.74 (95% CI: 0.57–0.96)].267. Here, TNF is linked to rheumatoid arthritis.